Published on 02/12/2025

Tech Transfer to Hospital Sites: PPQ/CPV Hooks

The process of tech transfer to hospital sites for biologics and Advanced Therapy Medicinal Products (ATMP) brings unique challenges and requirements, especially regarding Process Performance Qualification (PPQ) and Continued Process Verification (CPV). In this guide, we will cover essential aspects of PPQ and CPV tailoring for ATMP, with a focus on regulatory requirements and best practices.

Understanding the Basics of Tech Transfer and Its Importance

Tech transfer is the systematic transfer of a process from the development or manufacturing site to a new location, such as a hospital setting. This ensures that the quality and efficacy of the product are maintained throughout. The importance of successful tech transfer cannot be overstated, particularly when dealing with biologics and ATMP, given their complexity and the need for stringent compliance with regulatory guidelines such as those outlined by the FDA, EMA, and PIC/S.

During tech transfer, organizations must ensure that all aspects of the product’s manufacturing process are adequately documented and transferred. This includes understanding the key quality attributes (CQAs), which must be tracked and verified throughout the PPQ and CPV phases. Effective tech transfer helps minimize risks, enhances compliance, and ultimately ensures patient safety.

Regulatory Framework for PPQ and CPV in Biologics and ATMP

Regulations surrounding PPQ and CPV present significant implications for biologics and ATMPs. The ICH Q5A(R2) guidelines recommend a comprehensive understanding of viral clearance mechanisms and require that manufacturing processes minimize the risk of viral contamination. Viral clearance validation is crucial in this regard. Furthermore, regulation under Annex 1 emphasizes the need for stringent aseptic controls, particularly regarding closed and single-use systems.

To comply with these regulations, teams must grasp the milestones of PPQ and CPV. PPQ is the implementation of manufacturing processes under a predefined set of conditions, while CPV involves ongoing monitoring and validation of these processes to ensure they remain within control limits. A robust strategy for both PPQ and CPV is essential to demonstrate the process’s reliability and product quality consistently.

Planning the PPQ Strategy: Key Components

The planning phase for PPQ should consider various elements such as process design, equipment qualification, and raw material compliance. The following key components are vital in constructing an effective PPQ strategy:

• Process Understanding: Detailed characterization of the manufacturing process for ATMP is critical. All input variables should be defined, with a particular focus on those impacting CQAs.
• Risk Assessment: Conduct risk assessments to identify potential areas that could lead to variations in product quality.
• Appropriate Sampling Techniques: Sampling methodologies must be clearly defined to ensure representative data collection during validation.
• Spiking Studies: These studies are vital for assessing the viral clearance capacity of the process. Understanding the limits of detection and the effectiveness of mitigation steps is essential.
• Documenting the Chain of Identity Custody: It is crucial to maintain a detailed record of all materials and processes throughout the manufacturing cycle.

Engaging cross-functional teams during the planning phase can facilitate a deeper understanding and smoother execution of the PPQ process. Regulatory requirements will guide every aspect of planning, and thorough documentation will serve as an essential resource for proving compliance.

Conducting the Process Performance Qualification

The execution of the PPQ involves a series of steps designed to validate that the process works within defined parameters and consistently produces quality products. Below is a breakdown of the critical actions involved in carrying out PPQ for ATMP:

• Preparation of Validation Protocols: Establish comprehensive protocols for PPQ, tailored to the unique attributes of the ATMP being produced. These protocols must outline the methods and acceptance criteria used during the validation process.
• Execution of the Qualification: Execute the validation according to the established protocols. This may entail running multiple batches of the ATMP to determine if it meets the required specifications.
• Data Collection and Analysis: Collect and analyze data proficiently to assess process performance. This involves monitoring critical parameters and comparing them with established acceptance criteria.
• Documentation of Findings: Ensure all findings, deviations, and suggested corrective actions are well-documented. This provides traceability and supports future audits and inspections.
• Final Report and Review: Prepare a final report summarizing the PPQ findings and review them with relevant stakeholders, including quality, regulatory, and operational teams.

Performing PPQ in alignment with regulatory expectations supports compliance and ensures that the ATMP’s safety and efficacy are well understood and preserved throughout the manufacturing process.

Implementing Continued Process Verification

Once PPQ is completed, organizations must transition into the CPV phase, where continuous monitoring ensures that the process remains in a state of control. Several essential steps are involved in implementing CPV effectively:

• Establishing CPV Metrics: Define key metrics to be monitored during the production cycle. These metrics should align with the identified CQAs during the initial validation phase.
• Continuous Monitoring: Employ technology and systems that allow for real-time data collection and monitoring. This may include automated controls and software that can analyze data patterns.
• Regular Review of Data: Schedule periodic reviews of CPV data to assess trends and investigate any deviations from established limits. This proactive approach allows organizations to address potential issues before they escalate.
• Documentation: Thorough documentation of CPV activities is essential, serving as a part of the regulatory record that demonstrates ongoing compliance.
• Feedback Loops: Incorporate feedback from CPV findings into continuous improvement strategies. This may involve modifications to the manufacturing process or additional training for personnel.

The engagement of cross-functional teams within CPV supports collaborative problem-solving and a shared commitment to quality. Ongoing dialogues between production, quality assurance, and regulatory affairs teams can foster a culture of compliance and continuous improvement.

Addressing Challenges in Validation for ATMP

Validation processes for ATMP can present unique challenges, including complexity in product design, rapid technological advances, and evolving regulatory requirements. A few critical considerations to address these challenges include:

• Stakeholder Collaboration: Engaging internal and external stakeholders early in the process helps mitigate misunderstandings and aligns objectives and compliance needs.
• Adaptation to Technology: Organizations must be flexible in adopting new technologies that improve validation processes. Closed systems and single-use systems can streamline workflows but require clear validation frameworks.
• Resource Allocation and Training: Adequate resources, including time and knowledgeable personnel, are necessary for successful validation endeavors. Ongoing training programs ensure that staff remain current with regulatory developments and practices.
• Regulatory Engagement: Maintain open communications with regulatory authorities. Requesting feedback on validation approaches or proposed changes can help clarify requirements and enhance compliance.

Proactively addressing these challenges ensures that the validation processes for ATMPs meet both current and future regulatory requirements while optimizing manufacturing performance and patient safety.

The Future of PPQ/CPV in Hospital Settings

As the field of biologics and ATMP continues to evolve, so too will the approaches to PPQ and CPV. Industry trends indicate a move towards greater automation, real-time data monitoring, and predictive analytics to enhance compliance efforts. Advances in technology, including data science and machine learning, will provide novel solutions for addressing ongoing challenges in validation.

Moreover, regulatory frameworks will likely continue to evolve alongside scientific advancements. Constant engagement with regulatory bodies, as well as adaptation to new guidelines, will ensure that organizations remain compliant while promoting product efficacy and safety.

Conclusion

Tech transfer to hospital sites for biologics and ATMP involves a multifaceted approach to ensure that PPQ and CPV are tailored to meet stringent regulatory requirements. By understanding the regulatory landscape, implementing strategic planning, executing rigorous validation protocols, and fostering continuous process verification, organizations can enhance their compliance and elevate patient safety standards. As technology progresses and the industry evolves, staying informed and adaptable will be crucial to navigating the complexities of pharmaceutical validation in the context of biologics and ATMP.